AIMS/HYPOTHESIS: The Edmonton Protocol for islet transplantation has provided hope for type 1 diabetic patients. However, this protocol requires lifelong immunosuppression, specifically sirolimus, a cellular antiproliferate. The effect of sirolimus on human pancreatic ductal cells (HDCs) is not known. This may be important since HDCs are believed to be islet precursors. Since neonatal porcine islets (NPIs), which contain many ductal precursor cells, could be a potential clinical source of islets, we also tested the effects of sirolimus on this tissue. METHODS: HDCs (n=4), NPIs (n=9) and human islets (n=5) were cultured with and without sirolimus (20 ng/ml) for 6 days. RESULTS: HDCs and NPIs cultured with sirolimus showed a 50 and 28% decrease, respectively, in cell number relative to control (p<0.05). Control cultures expanded 1.65- and 2.44-fold relative to time 0. Decreases in cell number of sirolimus-treated HDCs were not due to apoptosis as measured by TUNEL staining. No functional effects on human islets or NPIs were observed following static incubation with high glucose. Treatment of syngeneically transplanted and naïve BALC/c mice with sirolimus resulted in altered OGTT profiles with prolonged elevation of hyperglycaemia and weight gain. There was no difference in graft and organ insulin content between treatment groups. CONCLUSIONS/ INTERPRETATION: Our results indicate that sirolimus decreases ductal cell numbers in culture and alters glucose-stimulated insulin secretion in vivo. The administration of sirolimus to islet transplant recipients is likely to impair graft function as a result of decreasing ductal neogenesis and induction of insulin resistance.
AIMS/HYPOTHESIS: The Edmonton Protocol for islet transplantation has provided hope for type 1 diabeticpatients. However, this protocol requires lifelong immunosuppression, specifically sirolimus, a cellular antiproliferate. The effect of sirolimus on humanpancreatic ductal cells (HDCs) is not known. This may be important since HDCs are believed to be islet precursors. Since neonatal porcine islets (NPIs), which contain many ductal precursor cells, could be a potential clinical source of islets, we also tested the effects of sirolimus on this tissue. METHODS: HDCs (n=4), NPIs (n=9) and human islets (n=5) were cultured with and without sirolimus (20 ng/ml) for 6 days. RESULTS: HDCs and NPIs cultured with sirolimus showed a 50 and 28% decrease, respectively, in cell number relative to control (p<0.05). Control cultures expanded 1.65- and 2.44-fold relative to time 0. Decreases in cell number of sirolimus-treated HDCs were not due to apoptosis as measured by TUNEL staining. No functional effects on human islets or NPIs were observed following static incubation with high glucose. Treatment of syngeneically transplanted and naïve BALC/c mice with sirolimus resulted in altered OGTT profiles with prolonged elevation of hyperglycaemia and weight gain. There was no difference in graft and organ insulin content between treatment groups. CONCLUSIONS/ INTERPRETATION: Our results indicate that sirolimus decreases ductal cell numbers in culture and alters glucose-stimulated insulin secretion in vivo. The administration of sirolimus to islet transplant recipients is likely to impair graft function as a result of decreasing ductal neogenesis and induction of insulin resistance.
Authors: Kenneth Cardona; Gregory S Korbutt; Zvonimir Milas; James Lyon; Jose Cano; Wanhong Jiang; Hameeda Bello-Laborn; Brad Hacquoil; Elizabeth Strobert; Shivaprakash Gangappa; Collin J Weber; Thomas C Pearson; Ray V Rajotte; Christian P Larsen Journal: Nat Med Date: 2006-02-26 Impact factor: 53.440
Authors: S Bonner-Weir; M Taneja; G C Weir; K Tatarkiewicz; K H Song; A Sharma; J J O'Neil Journal: Proc Natl Acad Sci U S A Date: 2000-07-05 Impact factor: 11.205
Authors: Cale N Street; Jonathan R T Lakey; Ray V Rajotte; A M James Shapiro; Timothy J Kieffer; James G Lyon; Tatsuya Kin; Gregory S Korbutt Journal: Rev Diabet Stud Date: 2004-08-10
Authors: Ewan Bell; Xiaopei Cao; Jacob A Moibi; Scott R Greene; Robert Young; Matteo Trucco; Zhiyong Gao; Franz M Matschinsky; Shaoping Deng; James F Markman; Ali Naji; Bryan A Wolf Journal: Diabetes Date: 2003-11 Impact factor: 9.461
Authors: Christiane J Bruns; Gudrun E Koehl; Markus Guba; Maksim Yezhelyev; Markus Steinbauer; Hendrik Seeliger; Astrid Schwend; Anna Hoehn; Karl-Walter Jauch; Edward K Geissler Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: Dietlind Zohlnhöfer; Thomas G Nührenberg; Franz-Josef Neumann; Thomas Richter; Andreas E May; Roland Schmidt; Katja Denker; Matthias A Clauss; Albert Schömig; Patrick A Baeuerle Journal: Mol Pharmacol Date: 2004-04 Impact factor: 4.436
Authors: N Deblon; L Bourgoin; C Veyrat-Durebex; M Peyrou; M Vinciguerra; A Caillon; C Maeder; M Fournier; X Montet; F Rohner-Jeanrenaud; M Foti Journal: Br J Pharmacol Date: 2012-04 Impact factor: 8.739
Authors: Jane Bryant; Kelan A Hlavaty; Xiaomin Zhang; Woon-Teck Yap; Lei Zhang; Lonnie D Shea; Xunrong Luo Journal: Biomaterials Date: 2014-07-25 Impact factor: 12.479
Authors: Hiroyuki Mori; Ken Inoki; Darren Opland; Heike Münzberg; Eneida C Villanueva; Miro Faouzi; Tsuneo Ikenoue; David J Kwiatkowski; Ormond A Macdougald; Martin G Myers; Kun-Liang Guan Journal: Am J Physiol Endocrinol Metab Date: 2009-08-18 Impact factor: 4.310